Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Genedit Inc.
Headquarters: South San Francisco, CA, United States of America
Website: http://www.genedit.com
Year Founded: 2016
Status: Private
BioCentury | Jul 30, 2024
Product Development
Venturing beyond AAVs and LNPs to deliver therapeutic cargo
Dozens of companies aim to avoid immunogenicity and improve tissue-specificity
BioCentury | Jan 30, 2024
Deals
Deals roundup: Novo-EraCal in second obesity deal, Roche gives back Hookipa’s HB-700, and more
BioCentury’s weekly roundup of biopharma deals, Jan. 23-29
BioCentury | Jan 26, 2024
Finance
VC roundup: Synnovation chases familiar targets, Mirae’s new U.S. firm backs Accent
Plus deals for GenEdit, Elephas and more
BioCentury | Dec 1, 2022
Finance
With second asset nearing clinic, Escient to test new mast cell targets with $120M series C
Newly backed by NEA, Abingworth and Forge, the biotech is advancing a MRGPRX2 program for urticaria behind its clinical asset for pruritus
BioCentury | Feb 3, 2022
Product Development
Feb. 2 Quick Takes: Pharming plans global submissions for leniolisib
Plus Novo ends Staten deal, new Pfizer vaccine data coming, Novartis scuttles pan-JAK and more
BioCentury | Sep 24, 2021
Product Development
Sept. 23 Quick Takes: $72M series A for stem cell newco Garuda
Plus: On deck at ODAC, GenEdit, Worg-Apitope, Reata, Tyvyt and more
Items per page:
1 - 10 of 10